Predicting prostate biopsy results using a panel of plasma and urine biomarkers combined in a scoring system

Journal of Cancer

Volumn 7, Issue 3, 2016, Pages 297-303

  Albitar, Maher ^a   Ma, Wanlong ^a   Lund, Lars ^b   Albitar, Ferras ^a   Diep, Kevin ^a   Fritsche, Herbert A ^c   Shore, Neal ^d  

^a NeoGenomics California   (United States)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c Health Discovery Corporation   (United States)

^d Carolina Urologic Research Center   (United States)

Author keywords

Algorithm; Cell free; Gleason; High grade; RNA; Scoring

Indexed keywords

ANDROGEN RECEPTOR; BETA 2 MICROGLOBULIN; CHAPERONIN 60; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTATE SPECIFIC ANTIGEN; TRANSCRIPTION FACTOR ERG; TUMOR MARKER;

ADULT; AGED; ALGORITHM; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; GENE; GENE EXPRESSION; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMPDH2 GENE; MALE; PCA3 GENE; PDLIM5 GENE; PREDICTIVE VALUE; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TMPRSS2 GENE; UAP1 GENE; URINALYSIS;

EID: 84971506880     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.12771     Document Type: Article

References (23)

1. Ankerst DP, Boeck A, Freedland SJ, Jones JS, Cronin AM, Roobol MJ, Hugosson J, Kattan MW, Klein EA, Hamdy F, Neal D, Donovan J, Parekh DJ, Klocker H, Horninger W, Benchikh A, Salama G, Villers A, Moreira DM, Schröder FH, Lilja H, Vickers AJ, Thompson IM. Evaluating the Prostate Cancer Prevention Trial High Grade Prostate Cancer Risk Calculator in 10 international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. World J Urol. 2014 Feb;32(1):185-191.
2. Guyon, Isabelle, Herbert Fritsche, Paul Choppa, Li-Ying Yang, Stephen Barnhill. A Four-Gene Expression Signature for Prostate Cancer Cells Consisting of UAP1, PDLIM5, IMPDH2, and HSPD1. UroToday International Journal 2009; 2(4): 3834-3844.
3. Zietman A. Evidence-based medicine, conscience-based medicine, and the management of low-risk prostate cancer. J Clin Oncol 2009; 27(30): 4935-4936.
4. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 2004; 350:2239-2246.
5. De Kok JB, Verhaegh GW, Roelofs RW, et al. DD3 (PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 2002; 62:2695-2698.
6. St John J, Powell K, Conley-Lacomb MK, et al. TMPRSS2-ERG fusion gene expression in prostate tumor cells and its clinical and biological significance in prostate cancer progression. J Cancer Sci Ther 2012; 4(4):94-101.
7. Prensner JR, Rubin MA, Wei JT, et al. Beyond PSA: The next generation of prostate cancer biomarkers. Sci Transl Med 2012; 4:127rv3.
8. Humphrey PA. Gleason grading and prognostic factors in carcinoma of the prostate. Med Pathol 2004; 17:292-306.
9. Carter HB, Partin AW, Walsh PC, et al. Gleason Score 6 adenocarcinoma: should it be labeled as cancer? J Clin Oncol 2012; 30(35):4294-4296.
10. Ma W, Diep K, Fritsche HA, et al. Diagnostic and prognostic scoring system for prostate cancer using urine and plasma biomarkers. Genet Test Mol Biomarkers 2014; 18(3):156-63.
11. De Velasco MA, Uemura H. Preclinical remodeling of human prostate cancer through the PTEN/AKT pathway. Adv Urol 2012; 2012:1-12.
12. Suzuki H, Freije D, Nusskern DR, et al. Interfocal heterogeneity of PTEN/MMAC1 gene alteration sin multiple metastatic prostate cancer tissues. Cancer Res 1998; 58:204-9.
13. Yoshimoto M, Cunha IW, Coudry RA, et al. FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br J Cancer 2007; 97:678-85.
14. Li Y, Gao Y, Xu Y, et al. si-RNA-Mediated Knockdown of PDLIM5 Suppresses Gastric Cancer Cell Proliferation in Vitro. Chem Biol Drug Des 2014; doi: 10.1111/cbdd.12428.
15. Donovan MJ, Osman I, Khan FM, et al. Androgen receptor expression is associated with prostate cancer-specific survival in castrate patients with metastatic disease. BJU Int 2010; 105(4):462-67.
16. Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010; 18(1):11-22.
17. Phin S, Moore MW, Cotter PD. Genomic rearrangements of PTEN in prostate cancer. Front Oncol. 2013; 3:240.
18. Jhaver A, Reid A, Clark J, et al. Detection of TMPRSS2-ERG translocations in human prostate cancer by expression profiling using GeneChip Human Exon 1.0 ST arrays. J Mol Diagnon 2008; 10(1): 50-7.
19. Bismar TA, Yoshimoto M, Vollmer RT, et al. PTEN genomic deletion is an early even associated with ERG gene rearrangements in prostate cancer. BJU Int 2011; 107(3):477-85.
20. Krohn A, Diedler T, Burkhardt L, et al. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. Am J Pathol 2012; 181(2):401-12.
21. Epstein JI, Allsbrook WC Jr, Amin MB, et al. Update on the Gleason grading system for prostate cancer: Results of an international consensus conference of urologic pathologists. Adv Anat Pathol 2006; 13(1):57-9.
22. Carter HB, Partin AW, Walsh PC, Trock BJ, Veltri RW, Nelson WG, Coffey DS, Singer EA, Epstein JI. Gleason score 6 adenocarcinoma: should it be labeled as cancer? J Clin Oncol. 2012; 30(35):4294-6.
23. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumor MARKer prognostic studies (REMARK). Nature Clinical Practice Oncology 2005; 2(8): 416-422.